Agustín
Albillos Martínez
Catedrático/a de Universidad
Juan
Turnes Vázquez
Juan Turnes Vázquez-rekin lankidetzan egindako argitalpenak (15)
2024
-
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis
Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597
2023
-
Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver
Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132
-
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B
Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
2019
-
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 579-592
2018
-
The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity
Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270
2017
-
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort
Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148
-
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Hepatology, Vol. 65, Núm. 6, pp. 1810-1822
2016
-
Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients with Cirrhosis
Gastroenterology, Vol. 150, Núm. 5, pp. 1160-1170.e3
2014
-
Terapia triple en pacientes con fibrosis avanzada y cirróticos: Aspectos relevantes en la práctica clínica
Gastroenterologia y Hepatologia, Vol. 37, Núm. S1, pp. 13-22
2009
-
Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial
Gastroenterology, Vol. 136, Núm. 5, pp. 1651-1658
2008
-
Portal Hypertension-Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation
Clinical Gastroenterology and Hepatology, Vol. 6, Núm. 12, pp. 1412-1417